All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lupus Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-07-24T15:45:57.000Z

Precision medicine in systemic lupus erythematosus

Jul 24, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in SLE.

During the 14th European Lupus Meeting 2024, the Lupus Hub was pleased to speak with Ioannis Parodis, Karolinska Institutet, Solna, SE. We asked about precision medicine in systemic lupus erythematosus (SLE). 

Precision medicine in systemic lupus erythematosus

Parodis highlights the emergence of approved targeted therapies, such as belimumab and anifrolumab, along with the recent approval of voclosporin for lupus nephritis. He emphasizes the importance of understanding the underlying mechanisms of SLE and its various clinical phenotypes. He anticipates a paradigm shift from traditional taxonomies towards molecular characterization of the disease. Parodis also shares his recent research on gene module analysis, where patients with lupus nephritis were grouped based on their interferon signature (low, intermediate, and high) and studied for their response to different therapies based on systems biology. Understanding which genetic signatures can be altered by targeting specific genes will allow us to apply targeted therapies more effectively in a personalized manner in the future. 

Newsletter

Subscribe to get the best content related to lupus delivered to your inbox